CGEM Valuation

Cullinan Therapeutics Inc

Add to Watchlist

Advanced Chart

6.450

+0.56(9.508%)1D

Overview
Forecast
Valuation
Earnings

CGEM Relative Valuation

CGEM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CGEM is overvalued; if below, it's undervalued.

Historical Valuation

Cullinan Therapeutics Inc (CGEM) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.78. The fair price of Cullinan Therapeutics Inc (CGEM) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：6.45

Fair

-1.54

Trailing

Forward

-0.35

EV/EBITDA

Cullinan Therapeutics Inc. (CGEM) has a current EV/EBITDA of -0.35. The 5-year average EV/EBITDA is -4.94. The thresholds are as follows: Strongly Undervalued below -30.17, Undervalued between -30.17 and -17.55, Fairly Valued between 7.67 and -17.55, Overvalued between 7.67 and 20.29, and Strongly Overvalued above 20.29. The current Forward EV/EBITDA of -0.35 falls within the Historic Trend Line -Fairly Valued range.

-0.31

EV/EBIT

Cullinan Therapeutics Inc. (CGEM) has a current EV/EBIT of -0.31. The 5-year average EV/EBIT is -4.27. The thresholds are as follows: Strongly Undervalued below -23.08, Undervalued between -23.08 and -13.67, Fairly Valued between 5.13 and -13.67, Overvalued between 5.13 and 14.53, and Strongly Overvalued above 14.53. The current Forward EV/EBIT of -0.31 falls within the Historic Trend Line -Fairly Valued range.

55.67

Cullinan Therapeutics Inc. (CGEM) has a current PS of 55.67. The 5-year average PS is 41.46. The thresholds are as follows: Strongly Undervalued below -74.01, Undervalued between -74.01 and -16.28, Fairly Valued between 99.19 and -16.28, Overvalued between 99.19 and 156.92, and Strongly Overvalued above 156.92. The current Forward PS of 55.67 falls within the Historic Trend Line -Fairly Valued range.

-1.85

P/OCF

Cullinan Therapeutics Inc. (CGEM) has a current P/OCF of -1.85. The 5-year average P/OCF is -7.82. The thresholds are as follows: Strongly Undervalued below -28.16, Undervalued between -28.16 and -17.99, Fairly Valued between 2.35 and -17.99, Overvalued between 2.35 and 12.52, and Strongly Overvalued above 12.52. The current Forward P/OCF of -1.85 falls within the Historic Trend Line -Fairly Valued range.

-1.81

P/FCF

Cullinan Therapeutics Inc. (CGEM) has a current P/FCF of -1.81. The 5-year average P/FCF is -6.06. The thresholds are as follows: Strongly Undervalued below -26.17, Undervalued between -26.17 and -16.11, Fairly Valued between 4.00 and -16.11, Overvalued between 4.00 and 14.05, and Strongly Overvalued above 14.05. The current Forward P/FCF of -1.81 falls within the Historic Trend Line -Fairly Valued range.

Cullinan Therapeutics Inc (CGEM) has a current Price-to-Book (P/B) ratio of 0.77. Compared to its 3-year average P/B ratio of 1.13 , the current P/B ratio is approximately -31.53% higher. Relative to its 5-year average P/B ratio of 1.32, the current P/B ratio is about -41.55% higher. Cullinan Therapeutics Inc (CGEM) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -26.89%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -19.30% , the current FCF yield is about -100.00% lower.

0.77

P/B

Median3y

1.13

Median5y

1.32

-49.30

FCF Yield

Median3y

-26.89

Median5y

-19.30

Competitors Valuation Multiple

The average P/S ratio for CGEM's competitors is 0.00, providing a benchmark for relative valuation. Cullinan Therapeutics Inc Corp (CGEM) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CGEM.O

Cullinan Therapeutics Inc

Aardvark Therapeutics Inc

LB Pharmaceuticals Inc

Loss

337.54M

CAPR.O

Capricor Therapeutics Inc

Loss

-100.00%

341.96M

Performance Decomposition

Market capitalization of CGEM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of CGEM in the past 1 year is driven by Unknown.